| Dose Finding in Drug Development Contributor(s): Ting, Naitee (Editor) |
|
 |
ISBN: 144192115X ISBN-13: 9781441921154 Publisher: Springer OUR PRICE: $161.49 Product Type: Paperback - Other Formats Published: November 2010 |
| Additional Information |
| BISAC Categories: - Medical | Biostatistics - Medical | Pharmacy - Medical | Pharmacology |
| Dewey: 615.19 |
| Series: Statistics for Biology and Health |
| Physical Information: 0.55" H x 6.14" W x 9.21" (0.82 lbs) 248 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: This book emphasizes dose selection issues from a statistical point of view. It presentsstatisticalapplicationsinthedesignandanalysisofdose-responsestudies. The importance of this subject can be found from the International Conference on Harmonization (ICH) E4 Guidance document. Establishing the dose-response relationship is one of the most important act- ities in developing a new drug. A clinical development program for a new drug can be broadly divided into four phases - namely Phases I, II, III, and IV. Phase I clinical trials are designed to study the clinical pharmacology. Information - tained from these studies will help in designing Phase II studies. Dose-response relationshipsareusuallystudiedinPhaseII.PhaseIIIclinicaltrialsarelarge-scale, long-term studies. These studies serve to con?rm ?ndings from Phases I and II. ResultsobtainedfromPhasesI, II, andIIIclinicaltrialswouldthenbedocumented and submitted to regulatory agencies for drug approval. In the United States, - viewers from Food and Drug Administration (FDA) review these documents and make a decision to approve or to reject this New Drug Application (NDA). If the new drug is approved, then Phase IV studies can be started. Phase IV clinical trials are also known as postmarketing studies. |